Skip to main content

Macugen

Volume 448: debated on Wednesday 28 June 2006

To ask the Secretary of State for Health what arrangements are in place for provision on the NHS of the drug Macugen for age-related macular degeneration in advance of a decision on licensing and National Institute for Health and Clinical Excellence appraisal; and if she will make a statement. (80635)

The Department has made it clear that patients should not be refused a treatment simply because guidance from the National Institute for Health and Clinical Excellence is unavailable. In these circumstances, we expect primary care trusts to take full account of available evidence when reaching decisions on whether to provide the treatment.